Tumour infiltrating lymphocytes and PD-L1 expression as potential predictors of outcome in patients with malignant pleural mesothelioma

N. Sobhani, G. Roviello, T. Pivetta, A. Ianza, D. Bonazza, F. Zanconati, F. Giudici, C. Bottin, S. P. Corona, A. Guglielmi, C. Rizzardi, M. Milione, M. Cortale, M. Confalonieri, D. Generali

Research output: Contribution to journalArticle

Abstract

Malignant pleural mesothelioma (MPM) is a rare and aggressive form of tumour. Some mesotheliomas have been proven to be highly immunogenic. Here, we investigated the correlation between tumour infiltrating lymphocytes (TILs) or programmed cell death ligand 1 (PD-L1) expression with overall survival (OS) in patients with MPM. 62 Paraffin-embedded formalin fixed (PEFF) samples were analysed for TILs and PD-L1 expression. Patients were divided in 4 groups according to a cut-off of the percentage of TILs found per sample as measured by immunohistichemistry: “0” or absent (between 0 and 5%), “1” or low (between 6 and 25%), “2” or moderate (between 26 and 50%) and “3” or high (between 51 and 75%). OS was then correlated with different TILs’ expression patterns. Moreover, PD-L1 expression was assessed within the tumour as well as in the adjacent stroma on the same samples. Higher expression of peritumoral TILs (Group 2 + 3) versus Group 0 and 1 correlated with improved OS (p-value = 0.02). On the contrary PD-L1 expression seemed to be inversely correlated with clinical outcomes, even in the absence of statistical significance (HR 1.76; p = 0.083 95% IC 0.92–3.36 in areas within the tumour; HR 1.60; p = 0.176 95%; IC 0.80–3.19 in areas within the stroma). No relationship between TILs and PD-L1 expression was identified. Our research supports the use of TILs and PD-L1 expression as potential outcome predictors in patients with MPM. The use of TILs and PD-L1 as biomarkers for checkpoint inhibitors’ efficacy warrants future investigation.

Original languageEnglish
Pages (from-to)2713-2720
Number of pages8
JournalMolecular Biology Reports
Volume46
Issue number3
DOIs
Publication statusPublished - Jun 1 2019

Fingerprint

Tumor-Infiltrating Lymphocytes
Cell Death
Ligands
Survival
Neoplasms
Malignant Mesothelioma
Mesothelioma
Paraffin
Formaldehyde
Biomarkers

Keywords

  • Immunotherapy
  • Malignant pleural mesothelioma
  • Programmed cell death-ligand 1
  • Tumour-infiltrating lymphocytes

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics

Cite this

Tumour infiltrating lymphocytes and PD-L1 expression as potential predictors of outcome in patients with malignant pleural mesothelioma. / Sobhani, N.; Roviello, G.; Pivetta, T.; Ianza, A.; Bonazza, D.; Zanconati, F.; Giudici, F.; Bottin, C.; Corona, S. P.; Guglielmi, A.; Rizzardi, C.; Milione, M.; Cortale, M.; Confalonieri, M.; Generali, D.

In: Molecular Biology Reports, Vol. 46, No. 3, 01.06.2019, p. 2713-2720.

Research output: Contribution to journalArticle

Sobhani, N, Roviello, G, Pivetta, T, Ianza, A, Bonazza, D, Zanconati, F, Giudici, F, Bottin, C, Corona, SP, Guglielmi, A, Rizzardi, C, Milione, M, Cortale, M, Confalonieri, M & Generali, D 2019, 'Tumour infiltrating lymphocytes and PD-L1 expression as potential predictors of outcome in patients with malignant pleural mesothelioma', Molecular Biology Reports, vol. 46, no. 3, pp. 2713-2720. https://doi.org/10.1007/s11033-019-04715-9
Sobhani, N. ; Roviello, G. ; Pivetta, T. ; Ianza, A. ; Bonazza, D. ; Zanconati, F. ; Giudici, F. ; Bottin, C. ; Corona, S. P. ; Guglielmi, A. ; Rizzardi, C. ; Milione, M. ; Cortale, M. ; Confalonieri, M. ; Generali, D. / Tumour infiltrating lymphocytes and PD-L1 expression as potential predictors of outcome in patients with malignant pleural mesothelioma. In: Molecular Biology Reports. 2019 ; Vol. 46, No. 3. pp. 2713-2720.
@article{a3238501f2a449a0b20dad0dd738cc5d,
title = "Tumour infiltrating lymphocytes and PD-L1 expression as potential predictors of outcome in patients with malignant pleural mesothelioma",
abstract = "Malignant pleural mesothelioma (MPM) is a rare and aggressive form of tumour. Some mesotheliomas have been proven to be highly immunogenic. Here, we investigated the correlation between tumour infiltrating lymphocytes (TILs) or programmed cell death ligand 1 (PD-L1) expression with overall survival (OS) in patients with MPM. 62 Paraffin-embedded formalin fixed (PEFF) samples were analysed for TILs and PD-L1 expression. Patients were divided in 4 groups according to a cut-off of the percentage of TILs found per sample as measured by immunohistichemistry: “0” or absent (between 0 and 5{\%}), “1” or low (between 6 and 25{\%}), “2” or moderate (between 26 and 50{\%}) and “3” or high (between 51 and 75{\%}). OS was then correlated with different TILs’ expression patterns. Moreover, PD-L1 expression was assessed within the tumour as well as in the adjacent stroma on the same samples. Higher expression of peritumoral TILs (Group 2 + 3) versus Group 0 and 1 correlated with improved OS (p-value = 0.02). On the contrary PD-L1 expression seemed to be inversely correlated with clinical outcomes, even in the absence of statistical significance (HR 1.76; p = 0.083 95{\%} IC 0.92–3.36 in areas within the tumour; HR 1.60; p = 0.176 95{\%}; IC 0.80–3.19 in areas within the stroma). No relationship between TILs and PD-L1 expression was identified. Our research supports the use of TILs and PD-L1 expression as potential outcome predictors in patients with MPM. The use of TILs and PD-L1 as biomarkers for checkpoint inhibitors’ efficacy warrants future investigation.",
keywords = "Immunotherapy, Malignant pleural mesothelioma, Programmed cell death-ligand 1, Tumour-infiltrating lymphocytes",
author = "N. Sobhani and G. Roviello and T. Pivetta and A. Ianza and D. Bonazza and F. Zanconati and F. Giudici and C. Bottin and Corona, {S. P.} and A. Guglielmi and C. Rizzardi and M. Milione and M. Cortale and M. Confalonieri and D. Generali",
year = "2019",
month = "6",
day = "1",
doi = "10.1007/s11033-019-04715-9",
language = "English",
volume = "46",
pages = "2713--2720",
journal = "Molecular Biology Reports",
issn = "0301-4851",
publisher = "Springer Netherlands",
number = "3",

}

TY - JOUR

T1 - Tumour infiltrating lymphocytes and PD-L1 expression as potential predictors of outcome in patients with malignant pleural mesothelioma

AU - Sobhani, N.

AU - Roviello, G.

AU - Pivetta, T.

AU - Ianza, A.

AU - Bonazza, D.

AU - Zanconati, F.

AU - Giudici, F.

AU - Bottin, C.

AU - Corona, S. P.

AU - Guglielmi, A.

AU - Rizzardi, C.

AU - Milione, M.

AU - Cortale, M.

AU - Confalonieri, M.

AU - Generali, D.

PY - 2019/6/1

Y1 - 2019/6/1

N2 - Malignant pleural mesothelioma (MPM) is a rare and aggressive form of tumour. Some mesotheliomas have been proven to be highly immunogenic. Here, we investigated the correlation between tumour infiltrating lymphocytes (TILs) or programmed cell death ligand 1 (PD-L1) expression with overall survival (OS) in patients with MPM. 62 Paraffin-embedded formalin fixed (PEFF) samples were analysed for TILs and PD-L1 expression. Patients were divided in 4 groups according to a cut-off of the percentage of TILs found per sample as measured by immunohistichemistry: “0” or absent (between 0 and 5%), “1” or low (between 6 and 25%), “2” or moderate (between 26 and 50%) and “3” or high (between 51 and 75%). OS was then correlated with different TILs’ expression patterns. Moreover, PD-L1 expression was assessed within the tumour as well as in the adjacent stroma on the same samples. Higher expression of peritumoral TILs (Group 2 + 3) versus Group 0 and 1 correlated with improved OS (p-value = 0.02). On the contrary PD-L1 expression seemed to be inversely correlated with clinical outcomes, even in the absence of statistical significance (HR 1.76; p = 0.083 95% IC 0.92–3.36 in areas within the tumour; HR 1.60; p = 0.176 95%; IC 0.80–3.19 in areas within the stroma). No relationship between TILs and PD-L1 expression was identified. Our research supports the use of TILs and PD-L1 expression as potential outcome predictors in patients with MPM. The use of TILs and PD-L1 as biomarkers for checkpoint inhibitors’ efficacy warrants future investigation.

AB - Malignant pleural mesothelioma (MPM) is a rare and aggressive form of tumour. Some mesotheliomas have been proven to be highly immunogenic. Here, we investigated the correlation between tumour infiltrating lymphocytes (TILs) or programmed cell death ligand 1 (PD-L1) expression with overall survival (OS) in patients with MPM. 62 Paraffin-embedded formalin fixed (PEFF) samples were analysed for TILs and PD-L1 expression. Patients were divided in 4 groups according to a cut-off of the percentage of TILs found per sample as measured by immunohistichemistry: “0” or absent (between 0 and 5%), “1” or low (between 6 and 25%), “2” or moderate (between 26 and 50%) and “3” or high (between 51 and 75%). OS was then correlated with different TILs’ expression patterns. Moreover, PD-L1 expression was assessed within the tumour as well as in the adjacent stroma on the same samples. Higher expression of peritumoral TILs (Group 2 + 3) versus Group 0 and 1 correlated with improved OS (p-value = 0.02). On the contrary PD-L1 expression seemed to be inversely correlated with clinical outcomes, even in the absence of statistical significance (HR 1.76; p = 0.083 95% IC 0.92–3.36 in areas within the tumour; HR 1.60; p = 0.176 95%; IC 0.80–3.19 in areas within the stroma). No relationship between TILs and PD-L1 expression was identified. Our research supports the use of TILs and PD-L1 expression as potential outcome predictors in patients with MPM. The use of TILs and PD-L1 as biomarkers for checkpoint inhibitors’ efficacy warrants future investigation.

KW - Immunotherapy

KW - Malignant pleural mesothelioma

KW - Programmed cell death-ligand 1

KW - Tumour-infiltrating lymphocytes

UR - http://www.scopus.com/inward/record.url?scp=85062790716&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062790716&partnerID=8YFLogxK

U2 - 10.1007/s11033-019-04715-9

DO - 10.1007/s11033-019-04715-9

M3 - Article

C2 - 30840203

AN - SCOPUS:85062790716

VL - 46

SP - 2713

EP - 2720

JO - Molecular Biology Reports

JF - Molecular Biology Reports

SN - 0301-4851

IS - 3

ER -